Brief: Vor Biopharma Files For Offering Of Up To 51 Million Common Shares By The Selling Stockholders - SEC Filing
U.S. STOCKS ON THE MOVE-Marvell, US energy companies, copper miners
U.S. STOCKS ON THE MOVE-Thor Industries, Mirion Technologies, ServiceNow
U.S. STOCKS ON THE MOVE-Micron, Roblox, Quanta Services
Vor Biopharma climbs after Stifel upgrades rating on autoimmune drug potential
Brief: Vor Bio Announces Oral Presentation Of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study
Brief: Vor Biopharma Files For 1-For-20 Reverse Stock Split - SEC Filing
Brief: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Hillenbrand, ImmunityBio, V2X
U.S. STOCKS ON THE MOVE-Lumentum Holdings, ImmunityBio, V2X
Vor Bio jumps after late-stage data for immune disorder drug
Vor Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Vor Bio Appoints Seasoned Biotech Executive Dallan Murray As Chief Commercial Officer
Brief: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Vor Biopharma Terminates CFO Han Choi
Brief: Vor Bio Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value
Vor Biopharma Inc expected to post a loss of 25 cents a share - Earnings Preview